For a 40-year-old woman with stage IVB ovarian cancer that had stopped responding to platinum drugs, hope arrived in the form of YL205. This is a novel antibody-drug conjugate that targets a specific protein on cancer cells and delivers a topoisomerase I inhibitor payload to destroy them. After 24 weeks of treatment, she achieved a complete radiological response. Her CA-125 levels, a blood marker for cancer activity, normalized to 3.5 units per milliliter. She maintained this stability for 48 weeks. Side effects were manageable, including mild neutropenia symptoms, and she did not stop the treatment. This case highlights the potential of next-generation therapies with optimized linker-payload technologies. However, this is a single-patient report. We cannot yet say if this works for everyone with platinum-resistant ovarian cancer. The evidence is limited to one person. Do not generalize these findings to the broader population based on this single experience. This represents the first clinical instance of a complete response observed with this agent.
Case report of YL205 antibody-drug conjugate in platinum-resistant ovarian carcinomaFirst patient achieves complete response with new ovarian cancer drug YL205
AI-generated summary of the cited source, checked by automated accuracy review. How we work
Key Takeaway
Consider this case report as preliminary evidence for YL205 in a single patient with platinum-resistant ovarian cancer.
This publication is a single-patient case report describing the use of YL205, a novel NaPi2b-targeting antibody-drug conjugate, in a 40-year-old woman with FIGO stage IVB, BRCA-wildtype high-grade serous ovarian carcinoma. The patient received YL205 at 2.0 mg/kg every 3 weeks. The authors report that a complete radiological response was achieved after 24 weeks and CA-125 normalized to 3.5 U/ml. The response remained stable through the 48-week follow-up period.
The case highlights a positive clinical outcome in a single patient with platinum-resistant disease. The authors note that this represents the first clinical instance of a complete response observed with this agent. Safety findings indicated manageable grade 1–2 neutropenia symptoms, with no serious adverse events reported.
Key limitations acknowledged by the authors include the single-patient design, which precludes any conclusions about efficacy or safety for the broader population. The authors underscore the potential of next-generation ADCs with optimized linker-payload technologies, but this relevance is restrained by the case report format.
Practice relevance is limited to hypothesis generation. Clinicians should not generalize these findings to the broader platinum-resistant ovarian cancer population based on this single case report.
What this means for you:
One patient with advanced ovarian cancer achieved a complete response with the new drug YL205 after 24 weeks. More on High-Grade Serous Ovarian Carcinoma
Immunohistochemical profiling helps differentiate synchronous primary breast invasive carcinoma from metastatic ovarian carcinoma
One woman diagnosed with two different types of cancer simultaneously
This case report and literature review describes a patient with concurrent primary breast cancer and metastatic high-grade serous ovarian ca…
A rare case reveals how one patient can have both breast and ovarian cancer at once, highlighting a complex diagnostic challenge.
Review of ovarian cancer treatments including olaparib, bevacizumab, and durvalumab discusses limitations and biomarkers
New drug combos target hidden cancer switches to stop resistance
This narrative review examines ovarian cancer management involving olaparib, bevacizumab, and durvalumab.
Hidden chemical changes in ovarian cancer cells help them hide from drugs, but new combinations might finally stop them from adapting and gr…
Relacorilant plus nab-paclitaxel improves overall survival in platinum-resistant ovarian cancer
New Drug Combo Extends Survival for Tough Ovarian Cancer Cases
In a phase 3 randomised controlled trial of 381 patients with platinum-resistant ovarian cancer, relacorilant plus nab-paclitaxel significan…
This combination offers a new, simpler option for patients who have run out of standard treatments.
Multidisciplinary management of mixed adenoneuroendocrine carcinoma of the gallbladder involves surgery and adjuvant chemotherapy
Rare gallbladder cancer type shows specific genetic markers and traits
This case report and literature review describes the clinical management of a patient with mixed adenoneuroendocrine carcinoma of the gallbl…
A rare form of gallbladder cancer, known as GB-MANEC, was identified in a patient who underwent surgery and chemotherapy with no recurrence …
View Original Abstract ↓
High-grade serous ovarian carcinoma (HGSOC) remains a formidable challenge in the platinum-resistant setting (PROC). In the post-PARP inhibitor (PARPi) era, prior exposure reshapes resistance mechanisms, necessitating a shift from traditional platinum-free interval definitions to biomarker-driven strategies. We report an exceptional response to a next-generation ADC and review the evolving therapeutic landscape.
A 40-year-old woman with FIGO stage IVB, BRCA-wildtype HGSOC developed rapid multi-drug resistance following neoadjuvant chemotherapy, optimal cytoreduction, and progression on maintenance olaparib/bevacizumab, gemcitabine, and a USP1 inhibitor. Following the identification of high NaPi2b expression (83% tumor proportion score), she initiated YL205, a novel NaPi2b-targeting antibody-drug conjugate (ADC) utilizing a topoisomerase I inhibitor payload, at 2.0 mg/kg every 3 weeks.
The patient achieved a sustained complete radiological response (CR) and CA-125 normalization 3.5U/ml after 24 weeks, remaining stable through 48 weeks treatment. This represents the first clinical instance of CR observed with this agent. Adverse events were limited to manageable grade 1–2 neutropenia symptoms.
This case underscores the potential of next-generation ADCs featuring optimized linker-payload technologies. By utilizing topoisomerase I inhibitors, agents like YL205 bypass microtubule-stabilization resistance induced by prior taxane exposure, while “bystander effects” address intratumoral heterogeneity. Longitudinal, biomarker-matched strategies and proactive toxicity management are essential to achieving deep tissue clearance in heavily pretreated HGSOC.
Intrawound tobramycin plus vancomycin did not reduce deep infection risk compared with vancomycin alone in high-risk tibial fractures
Adding Antibiotics to Bone Surgery Didn't Lower Infection Risk
Related in Infectious Disease
Cefdinir and cefprozil show superior eradication rates compared to penicillin V for Group A streptococcal pharyngitis
Certain antibiotics work better than others for strep throat
This network meta-analysis of 64 RCTs involving 23,287 participants evaluated 24 antibiotics for Group A streptococcal (GAS) pharyngitis. Th…
New data shows that while some antibiotics effectively clear strep throat, azithromycin performs poorly and carries more risks.
Vonoprazan-amoxicillin dual therapy is a safe alternative to bismuth-containing quadruple therapy for H. pylori
New vonoprazan treatments show promise for clearing H. pylori infection
This multicenter randomized controlled trial of 579 H. pylori-positive patients found that vonoprazan-amoxicillin (VA) dual therapy demonstr…
Two new simplified drug combinations could offer a simpler way to clear H. pylori infections, especially for patients with certain allergies…
Favipiravir co-administration with lopinavir-ritonavir increased favipiravir clearance by twofold in COVID-19 patients
Trial shows favipiravir and lopinavir-ritonavir do not stop COVID-19
This Phase 2a randomized, double-blind, 2x2 factorial placebo-controlled trial evaluated favipiravir and lopinavir-ritonavir in patients wit…
A new trial reveals that combining favipiravir with lopinavir-ritonavir did not show antiviral activity against the virus in patients with C…
Evaluating Enhanced Intervention Strategies for Trachoma Elimination in Rural Ethiopian Communities
Enhanced treatment shows no extra benefit for children with trachoma
A cluster-randomized trial evaluates if adding fly control and hygiene behaviors to azithromycin dosing reduces trachoma prevalence.
A three-year study in Ethiopia found that adding extra fly control and hygiene measures did not lower infection rates more than standard dru…
From Other Specialties
Virtual reality exercise training improves walking capacity and reduces fall risk in older adults
Virtual reality exercise boosts walking and cuts fall risk in older adults
This meta-analysis of 2927 healthy older adults found that virtual reality (VR) based exercise training significantly improved six-minute wa…
Older adults who did VR-based exercise walked farther, moved faster, and felt less afraid of falling, a new analysis of 2,927 people finds.
Social isolation and loneliness are associated with increased frailty risk in general populations
Social isolation and loneliness increase the risk of physical frailty
This meta-analysis of 78,769 individuals found that social isolation and loneliness significantly increase the risk of frailty. Specifically…
Feeling alone or isolated can lead to a higher risk of frailty, making it harder for older adults to stay strong and independent.
Sarcopenia is associated with 2.30 higher odds of cognitive impairment in Latin American adults
Sarcopenia Linked to Higher Risk of Cognitive Impairment
This systematic review and meta-analysis of 8 studies involving 13,395 community-dwelling adults in Latin America found that sarcopenia is s…
A large review of data from Latin America shows that muscle loss in older adults is linked to a much higher risk of cognitive impairment.
Esketamine reduces 3-month postpartum depression incidence from 20.89% to 11.59% in primiparae
Trial shows esketamine reduces postpartum depression risk in new mothers
This randomized controlled trial of 322 primiparae found that a single dose of esketamine significantly reduced the incidence of postpartum …
A clinical trial suggests that a single dose of esketamine during C-section surgery may lower the risk of developing postpartum depression.